Kartik Rachakonda

Kartik Rachakonda

Auto-generated profile, based on publicly available information

Kartik Rachakonda

Undergraduate Studies, School of Arts and Sciences, University of South Florida, Tampa, FL 33620, USA

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 September 2022 in Cancers
Verified
Journal Article
Open access
PDF file
ABAmita R Banga
Amita R Banga
Peace OdiasePeace Odiase
Peace Odiase
KRKartik Rachakonda
Kartik Rachakonda
AGAmar Prakash Garg
Amar Prakash Garg
SASamuel E. Adunyah
Samuel E. Adunyah
GRGirish Rachakonda
Girish Rachakonda
Claudin-4 is part of the Claudin family of transmembrane tight junction (TJ) proteins found in almost all tissues and, together with adherens junctions and desmosomes, forms epithelial and endothelial junctional complexes. Although the distribution of Claudin-4 occurs in many cell types, the level of expression is cell-specific. Claudin proteins regulate cell proliferation and differentiation by binding cell-signaling ligands, and its expression is upregulated in several cancers. As a result, alterations in Claudin expression patterns or distribution are vital in the pathology of cancer. Profiling the genetic expression of Claudin-4 showed that Claudin-4 is also a receptor for the clostridium perfringens enterotoxin (CPE) and that Claudin-4 has a high sequence similarity with CPE’s high-affinity receptor. CPE is cytolytic due to its ability to form pores in cellular membranes, and CPE treatment in breast cancer cells have shown promising results due to the high expression of Claudin-4. The C-terminal fragment of CPE (c-CPE) provides a less toxic alternative for drug delivery into breast cancer cells, particularly metastatic tumors in the brain, especially as Claudin-4 expression in the central nervous system (CNS) is low. Therefore, c-CPE provides a unique avenue for the treatment of breast–brain metastatic tumors.